{ "items" : [
    { "id" : "http://webisa.webdatacommons.org/379084164"
      "properties" : {
        "http://www.w3.org/1999/02/22-rdf-syntax-ns#type" : [ "http://www.w3.org/ns/prov#Entity" ] ,
        "http://www.w3.org/ns/prov#value" : [ "ations of the disorder; 7) reduces the risk that the individual will develop the disorder; and 8) reduces the amount of a therapeutic agent, other than a TLR agonist, that needs to be administered. [0050] In some embodiments, an ???effective amount??? of a TLR agonist is an amount that results in a reduction of at least one pathological parameter or symptom associated with interstitial lung diseas" ] ,
        "http://www.w3.org/ns/prov#wasQuotedFrom" : [ "google.fr" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/255607138"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/379084164"] } } }
